 SALT LAKE CITY, Sept. 13, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and intellectual property IP, including the Vectra test, from Myriad Genetics autoimmune business unit to Labcorp NYSE: LH for 150 million in cash. Labcorp is a leading global life sciences company and one of the nations largest laboratory service providers. 